Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for …Markets InsiderCelyad (Paris:CYAD) (Brussels:CYAD) (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company, today announced that it will host a Key Op… Continue reading
|
Can gene therapy be harnessed to fight the AIDS virus?
ABC News For more than a decade, the strongest AIDS drugs could not fully control Matt Chappell’s HIV infection. Now his body controls it by itself, and researchers are trying to perfect the gene editing that made this possible. Scientists removed some of his … |
|
Can gene therapy be harnessed to fight the AIDS virus?
ABC News For more than a decade, the strongest AIDS drugs could not fully control Matt Chappell’s HIV infection. Now his body controls it by itself, and researchers are trying to perfect the gene editing that made this possible. Scientists removed some of his … |
Business Wire (press release) |
France’s Cellectis wins US patents for gene editing technology
Business Insider “These inventions are based on the early work initiated by inventors at Cellectis when the CRISPR technology first came to light,” the company said. CRISPR, an abbreviation of Clustered Regularly Interspaced Short Palindromic Repeats, forms the basis … Two Issued US Patents Granted to Cellectis for CRISPR Use in T-CellsBusiness Wire (press release) |
Business Wire (press release) |
France’s Cellectis wins US patents for gene editing technology
Channel NewsAsia “These inventions are based on the early work initiated by inventors at Cellectis when the CRISPR technology first came to light,” the company said. CRISPR, an abbreviation of Clustered Regularly Interspaced Short Palindromic Repeats, forms the basis … Two Issued US Patents Granted to Cellectis for CRISPR Use in T-CellsBusiness Wire (press release) |
Business Wire (press release) |
France’s Cellectis wins U.S patents for gene editing technology
Reuters The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday. Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T …Business Wire (press release) |
Business Wire (press release) |
Two Issued US Patents Granted to Cellectis for CRISPR Use in T-Cells
Business Wire (press release) Convinced of their strong value for the future development of engineered CAR T-cells, Cellectis will make these patents available for licensing to companies that are willing to use CRISPR technologies in T-cells. The technical knowledge in these … France’s Cellectis wins US patents for gene editing technologyWHTC |